Adjuvant Capecitabine for Biliary Cancer and the Importance of Looking Beyond P-Values

被引：0
|
作者：
Fojo, Antonio Tito [1 ,2 ]
Neugut, Alfred, I [1 ,2 ]
机构：
[1] Columbia Univ, Irving Med Ctr, Herbert Irving Comprehens Canc Ctr, Dept Med,Div Hematol Oncol, New York, NY USA
[2] Columbia Univ, Irving Med Ctr, Herbert Irving Comprehens Canc Ctr, Dept Med,Div Hematol Oncol, New York, NY 10032 USA
来源：
ONCOLOGIST | 2024年 / 29卷 / 02期
关键词：
D O I：
10.1093/oncolo/oyad203
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：102 / 105
页数：4
相关论文
共 38 条
  • [31] Postoperative adjuvant tislelizumab plus lenvatinib and capecitabine for biliary tract cancer: Interim results of a prospective, single-arm, phase II study
    Feng, Y.
    Zhang, N.
    Zhao, Y.
    Pan, Q.
    Mao, A.
    Zhu, W.
    Lin, Z.
    Wang, L.
    Wang, Y. L.
    Zhou, J.
    Zhang, T.
    Wang, L.
    ANNALS OF ONCOLOGY, 2024, 35 : S119 - S119
  • [32] Adjuvant tislelizumab combined with capecitabine for patients with biliary tract cancer with high risk of postoperative relapse (ACTIVE): Primary analysis from a prospective cohort study
    Yang, Luyu
    Lu, Lu
    Wang, Xiangyu
    Sun, Haoting
    Zhu, Ying
    Xu, Da
    Yang, Jimeng
    Yin, Baobing
    Yang, Xin
    Zhu, Wenwei
    Jia, Huliang
    Chen, Jinhong
    Qin, Lunxiu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [33] BILCAP: A randomized clinical trial evaluating adjuvant chemotherapy with capecitabine compared to expectant treatment alone following curative surgery for biliary tract cancer.
    Bridgewater, J. A.
    Stubbs, C.
    Primrose, J. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [34] A randomized, multi-center phase III trial of adjuvant chemotherapy with gemcitabine and capecitabine (GemCap) compared to capecitabine (Cap) alone in curatively resected biliary tract cancer (BilGemCap Study): KCSG HB20-14.
    Park, Joon Oh
    Park, Joon Seong
    Lee, Choong-kun
    Chon, Hong Jae
    Choi, Sae Byeol
    Hwang, Dae Wook
    Oh, Do-Youn
    Lee, Myung Ah
    Jang, Jin-Young
    Ryoo, Baek-Yeol
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS633 - TPS633
  • [35] Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non-small-cell lung cancer
    Tsao, Ming-Sound
    Aviel-Ronen, Sarit
    Ding, Keyue
    Lau, Davina
    Liu, Ni
    Sakurada, Akira
    Whitehead, Marlo
    Zhu, Chang-Qi
    Livingston, Robert
    Johnson, David H.
    Rigas, James
    Seymour, Lesley
    Winton, Timothy
    Shepherd, Frances A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) : 5240 - 5247
  • [36] P-move: a randomized control trial of exercise in patients with advanced pancreatic or biliary tract cancer (aPBC) receiving beyond first-line chemotherapy
    De Lazzari, Nico
    Goette, Miriam
    Kasper, Stefan
    Meier, Eileen
    Schuler, Martin
    Pogorzelski, Michael
    Siveke, Jens T.
    Tewes, Mitra
    SUPPORTIVE CARE IN CANCER, 2024, 32 (07)
  • [37] A retrospective analysis of the efficacy and safety of capecitabine plus oxaliplatin (CapeOX) and docetaxel plus S-1 (DS) as adjuvant chemotherapy for pathological stage III (p stage III) gastric cancer (GC).
    Imai, Toru
    Hirano, Hidekazu
    Shoji, Hirokazu
    Hirose, Toshiharu
    Okita, Natsuko Tsuda
    Takashima, Atsuo
    Kato, Ken
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 342 - 342
  • [38] Prognostic Value of Expression of Kit67, p53, TopoIIα and GSTP1 for Curatively Resected Advanced Gastric Cancer Patients Receiving Adjuvant Paclitaxel plus Capecitabine Chemotherapy
    Zha, Yong
    Cun, Yingli
    Zhang, Qi
    Li, Yong
    Tan, Jing
    HEPATO-GASTROENTEROLOGY, 2012, 59 (117) : 1327 - 1332
1234